Cargando…
Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology
[Image: see text] GlycoConnect technology can be readily adapted to provide different drug-to-antibody ratios (DARs) and is currently also evaluated in various clinical programs, including ADCT-601 (DAR2), MRG004a (DAR4), and XMT-1660 (DAR6). While antibody-drug conjugates (ADCs) typically feature a...
Autores principales: | de Bever, Laureen, Popal, Sorraya, van Schaik, Jord, Rubahamya, Baron, van Delft, Floris L., Thurber, Greg M., van Berkel, Sander S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020967/ https://www.ncbi.nlm.nih.gov/pubmed/36857521 http://dx.doi.org/10.1021/acs.bioconjchem.2c00611 |
Ejemplares similares
-
Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering
por: Wijdeven, Marloes A., et al.
Publicado: (2022) -
Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
por: Dong, Shujun, et al.
Publicado: (2022) -
Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus
por: Banerjee, Avik, et al.
Publicado: (2022) -
The upcoming synthetic ultrapotent opioid wave as a foreseeable disaster
por: Krausz, R Michael, et al.
Publicado: (2022) -
Novel Vaccine That Blunts Fentanyl Effects and Sequesters
Ultrapotent Fentanyl Analogues
por: Barrientos, Rodell C., et al.
Publicado: (2020)